Reduced-intensity stem cell transplantation for acute myeloid leukemia with fludarabine-based conditioning with intravenous busulfan versus melphalan

Reduced-intensity conditioning (RIC) has been facilitating allogeneic hematopoietic cell transplantation (allo-HCT) for patients originally considered ineligible for HCT with myeloablative conditioning. Fludarabine (Flu) with reduced doses of busulfan (Bu) (Flu + Bu) and Flu with reduced doses of me...

Full description

Saved in:
Bibliographic Details
Published in:Bone marrow transplantation (Basingstoke) 2020-10, Vol.55 (10), p.1955-1965
Main Authors: Yamashita, Takuya, Takami, Akiyoshi, Uchida, Naoyuki, Fukuda, Takahiro, Eto, Tetsuya, Shiratori, Souichi, Ota, Shuichi, Akasaka, Takashi, Miyakoshi, Shigesaburo, Kondo, Tadakazu, Hidaka, Michihiro, Kanda, Junya, Atsuta, Yoshiko, Yano, Shingo
Format: Article
Language:English
Subjects:
692/308/2779/109/2154
692/699/1541/1990/283/1897
Acute myeloid leukemia
Adult
Analysis
Antimitotic agents
Antineoplastic agents
Busulfan
Cancer
Cell Biology
Conditioning
Confidence intervals
Disease control
Fludarabine
Graft vs Host Disease
Health aspects
Hematology
Hematopoietic Stem Cell Transplantation
Hematopoietic stem cells
Humans
Influenza
Internal Medicine
Intravenous administration
Leukemia
Leukemia, Myeloid, Acute - therapy
Medical colleges
Medicine
Medicine & Public Health
Melphalan
Multivariate analysis
Myeloid leukemia
Oncology, Experimental
Public Health
Retrospective Studies
Stem cell transplantation
Stem Cells
Survival
Transplantation
Transplantation Conditioning
Vidarabine - analogs & derivatives
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Reduced-intensity conditioning (RIC) has been facilitating allogeneic hematopoietic cell transplantation (allo-HCT) for patients originally considered ineligible for HCT with myeloablative conditioning. Fludarabine (Flu) with reduced doses of busulfan (Bu) (Flu + Bu) and Flu with reduced doses of melphalan (Mel) (Flu + Mel) are widely used RIC regimens for acute myeloid leukemia (AML). A nationwide retrospective study comparing clinical outcomes of adult patients with AML receiving first allo-HCT after RIC between 2001 and 2010 was performed. Cumulative incidences of relapse were not significantly different among the Flu + ivBu-based (FBiv), Flu + poBu-based (FBpo), and Flu + Mel-based (FM) groups ( p  = 0.29). Non-relapse mortality (NRM) was significantly lower in patients receiving FBiv compared with FBpo ( p  = 0.003) and FM ( p  
ISSN:0268-3369
1476-5365
DOI:10.1038/s41409-020-0856-y